From May 5 to 7, 2017, the 13th " 2017 PKU diabetes forum" jointly sponsored by Peking University diabetes center and China diabetes journal was successfully held in Beijing conference center. The " PKU diabetes forum " adheres to the tenet of " science first and academic independence" and provides comprehensive, in-depth and cutting-edge academic information exchange opportunities for Chinese clinicians and researchers related to diabetes. It is an important platform for academic research and exchange on diabetes at home and abroad and a weathervane for research on diabetes prevention and control in our country. This forum will introduce and discuss new methods, new evidence and new strategies for diabetes treatment under the theme of " new progress in diabetes drug treatment - from molecules to strategies".

Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the forum and made a report on " saving TZD--research and development progress of PPAR agonists" in a special forum of new molecules and new hopes. The report summarized the progress and challenges of drug clinical treatment under the background of the current emphasis on the integrated management of diabetes and its complications. Based on the development course and clinical advantages and disadvantages of TZD drugs, the scientific basis and potential clinical advantages of developing PPAR agonists were discussed. Finally, the preliminary research and the latest clinical trial progress of Chiglitazar, a new anti-type 2 diabetes drug, are introduced, which aroused the international attention.

Chiglitazar is a new generation of insulin sensitizer candidate drug independently designed, synthesized, screened and developed by CHIPSCREEN BIOSCIENCES. It is also the first original chemical class 1.1 new drug for treating type 2 diabetes in our country as well as a major national drug discovery project. Currently, Chiglitazar sodium is undergoing phase III clinical trials.

The grand occasion of the conference was unprecedented with 3,016 participants, bringing together many clinical and scientific research workers, experts and scholars engaged in diabetes prevention and control and related specialties at home and abroad. The experts attending the conference had two-day academic exchange and communication. The cutting-edge academic content, authoritative interpretation and comments provided a gluttonous academic feast for the vast number of participants.